Optimi Health Provides Progress Report On Year Of Commercialization
September 1, 2022
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets, is pleased to... Read more
Adastra Receives Controlled Substances Dealer’s License
August 31, 2022
Ryan Allway August 31st, 2022 News, Top News LANGLEY, BC / ACCESSWIRE / August 31, 2022 / Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to announce that the Company has... Read more
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
December 21, 2021
Ryan Allway December 21st, 2021 Psychedelics VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is... Read more
